Table 2.
Characteristics of Patients in Cohort 2. Characteristics of patients referred for COVID-19 vaccine clearance following PEG (not including mRNA vaccines), polysorbate, vaccine, and paclitaxel reactions are shown. The number of documented allergies ranges from zero as not all reported reactions were documented as an allergy in the EMR.
| Characteristics | All (n = 44) | Received vaccine (n = 33) |
|---|---|---|
| Age in y at time of referral, median (range) | 51 (18-80) | 48 (18-80) |
| Female sex at birth, n (%) | 37 (84) | 28 (85) |
| Race and Ethnicity, n (%) White Hispanic or Latino Black Asian American Indian Multiracial Other or unknown |
28 (64) — 2 (5) 3 (7) 1 (2) — 10 (23) |
21 (64) — 2 (6) 3 (9) — — 7 (21) |
| Primary language, n (%) English Farsi Russian |
42 (96) 1 (2) 1 (2) |
32 (97) 1 (3) — |
| Documented allergies in EMR, median (range) | 2 (0-52) | 2 (0-25) |
| Comorbidities, n (%) Drug allergy Food allergy Environmental allergy Asthma History of anaphylaxis Atopic dermatitis Urticaria/angioedema Anxiety |
35 (80) 8 (18) 20 (46) 14 (32) 21 (48) 7 (16) 7 (16) 30 (68) |
27 (82) 8 (24) 15 (46) 12 (36) 16 (49) 6 (18) 7 (21) 22 (67) |
| Reaction history consistent with | ||
| Allergy to medication containing PEG, n | 9 | 8 (5 Pfizer, 2 Moderna, 1 J&J) |
| Allergy to vaccine or medication containing polysorbate, n | 11 | 7 (4 Pfizer, 2 Moderna, 1 J&J) |
| Allergy to vaccine without polysorbate, n | 3 | 2 (1 Pfizer, 1 J&J) |
| Allergy to paclitaxel, n | 3 | 3 (2 Pfizer, 1 Moderna) |
| Inconsistent with allergy, n | 18 | 13 (8 Pfizera, 5 Moderna) |
Abbreviations: COVID-19, coronavirus disease 2019; EMR, electronic medical record; GBS, Guillain-Barré syndrome; mRNA, messenger RNA.
a
One patient with history of GBS after influenza vaccine declined second dose. All other patients received at least 2 doses of mRNA COVID-19 vaccine.